CTCL
55 programs · 53 companies
Programs
55
Companies
53
Trials
51
MOAs
39
CDK2iRAS(ON)iSHP2iPD-1iGLP-1/GIPKRASG12CiEGFRiCGRPantTNFiIL-23i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-3951 | Phase 2/3 | TNFα | ||
| SNY-9073 | Phase 2 | B7-H3 | ||
| Sovafutibatinib | Approved | FcRn | ||
| Cevinaritide | Phase 2/3 | DLL3 | ||
| Pemiinavolisib | NDA/BLA | CD47 | ||
| Pexaosocimab | NDA/BLA | PLK4 | ||
| Fixafutibatinib | Phase 3 | PRMT5 | ||
| APG-2066 | Phase 2 | TNFα | ||
| Rimatinib | Phase 1 | CD20 | ||
| Motatinib | Preclinical | MDM2 | ||
| CSL-652 | Preclinical | PSMA | ||
| 451-5171 | Preclinical | KRASG12D | ||
| ONC-2103 | Phase 1/2 | Tau | ||
| Rimalucimab | Phase 3 | FcRn | ||
| Pexainavolisib | Approved | SOS1 | ||
| VIG-1206 | Phase 3 | CFTR | ||
| Datocilimab | Approved | FLT3 | ||
| ELE-7872 | Phase 2/3 | BCL-2 | ||
| ENT-2952 | Phase 3 | JAK2 | ||
| Doxarapivir | Phase 2 | EGFR | ||
| Bemacapivasertib | Phase 2 | IL-23 | ||
| Gozederotide | Preclinical | EZH2 | ||
| Lisocagene | Phase 1 | AuroraA | ||
| Miricapivasertib | Phase 3 | PRMT5 | ||
| AGO-242 | Preclinical | CD19 | ||
| Zenonesiran | Preclinical | CD20 | ||
| Doxarasimod | Phase 3 | GLP-1R | ||
| COR-2320 | Preclinical | WEE1 | ||
| GLO-4270 | Phase 1 | CFTR | ||
| Talarasimod | Phase 1/2 | AuroraA | ||
| Elrasertib | Phase 3 | TIGIT | ||
| CAR-9866 | Phase 3 | CD38 | ||
| Nirafotisoran | Preclinical | SMN2 | ||
| Mavuzanubrutinib | Phase 1/2 | IL-17A | ||
| SPA-2229 | Phase 1 | KIF18A | ||
| SEN-3594 | Phase 2/3 | LAG-3 | ||
| CCC-2073 | Phase 1/2 | AuroraA | ||
| Voxarapivir | NDA/BLA | B7-H3 | ||
| NAT-2164 | Phase 1/2 | RET | ||
| Sotozanubrutinib | Phase 1/2 | IL-17A | ||
| Zenosertib | Phase 2/3 | FXIa | ||
| Kemasacituzumab | Approved | HER2 | ||
| Ivotinib | Phase 3 | BTK | ||
| Lisonesiran | Phase 2 | PRMT5 | ||
| Motazumab | Phase 3 | PARP | ||
| SLN-6859 | Phase 2 | GPRC5D | ||
| LAB-3189 | Phase 3 | BET | ||
| SIA-2247 | Preclinical | FLT3 | ||
| Elrabrutinib | Phase 2 | USP1 | ||
| Rimavorutinib | Phase 3 | PARP | ||
| TEV-5361 | Preclinical | MALT1 | ||
| NAT-IIT-130 | Phase 1 | KIF18A | ||
| Capifotisoran | Approved | TIGIT | ||
| QTR-9473 | Approved | GLP-1R | ||
| CER-9073 | Phase 1 | JAK1 |
Trials (51)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT08029422 | Sovafutibatinib | Approved | Active |
| NCT04809843 | Cevinaritide | Phase 2/3 | Recruiting |
| NCT03856432 | Fixafutibatinib | Phase 3 | Terminated |
| NCT08329190 | Rimatinib | Phase 1 | Active |
| NCT03373745 | Rimatinib | Phase 1 | Recruiting |
| NCT07876719 | CSL-652 | Preclinical | Terminated |
| NCT03976142 | ONC-2103 | Phase 1/2 | Not yet recr... |
| NCT04489412 | Rimalucimab | Phase 3 | Completed |
| NCT08057825 | Rimalucimab | Phase 3 | Not yet recr... |
| NCT08353120 | Pexainavolisib | Approved | Not yet recr... |
| NCT05646988 | Pexainavolisib | Approved | Completed |
| NCT03309524 | ELE-7872 | Phase 2/3 | Active |
| NCT08871581 | ELE-7872 | Phase 2/3 | Completed |
| NCT07690229 | ENT-2952 | Phase 3 | Terminated |
| NCT08235057 | ENT-2952 | Phase 3 | Terminated |
| NCT06319060 | Doxarapivir | Phase 2 | Recruiting |
| NCT06187141 | Gozederotide | Preclinical | Not yet recr... |
| NCT08767975 | Miricapivasertib | Phase 3 | Recruiting |
| NCT08530517 | Zenonesiran | Preclinical | Recruiting |
| NCT03273558 | Doxarasimod | Phase 3 | Not yet recr... |